Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.54%
#4 aPriori aPriori +175.89%
#5 Bedrock Bedrock +77.61%
#6 Cysic Cysic +53.64%
#7 Prom Prom +47.31%
#8 Playnance Playnance +34.87%
#9 Bitway Bitway +28.74%
#10 COTI COTI +27.09%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Rank in Stocks #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Share Price
$0.0009
Last synced: 2025-05-27
Market Cap
$1.15K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Arch Therapeutics, Inc. (ARTH)

Category

Healthcare
P/E ratio for Arch Therapeutics, Inc. (ARTH)
P/E ratio as of August 2026 TTM: 0.00
According to Arch Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.00. At the end of 2022 the company had a P/E ratio of -1.08.
P/E ratio history for Arch Therapeutics, Inc. from 2011 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 0.00 -100.00%
2023 -0.57 -46.88%
2022 -1.08 -75.26%
2021 -4.35 -99.73%
2020 -1.62K -44.60%
2019 -2.93K 15.52%
2018 -2.54K -14.51%
2017 -2.97K 7.68%
2016 -2.76K 88.35%
2015 -1.46K 390.49%
2014 -298.39 -75.27%
2013 -1.21K -57.39%
2012 -2.83K -93.43%
2011 -43.07K 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.